Literature DB >> 2965136

Teicoplanin in infections caused by methicillin-resistant staphylococci.

Y J Drabu1, B Walsh, P H Blakemore, S Mehtar.   

Abstract

Serious infections by methicillin-resistant staphylococci, 26 caused by Staphylococcus aureus and two by coagulase-negative staphylococci, were treated with teicoplanin 200-800 mg daily, in eight cases supplemented with another antibiotic. The overall rate of clinical cure or improvement was 75%, and that of bacterial eradication 67%.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2965136     DOI: 10.1093/jac/21.suppl_a.89

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

1.  Comparative Study of Teicoplanin vs Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteraemia.

Authors:  C Y Liu; W S Lee; C P Fung; N C Cheng; C L Liu; S P Yang; S L Chen
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

Review 2.  Anti-infective treatment in intensive care: the role of glycopeptides.

Authors:  R N Grüneberg; A P Wilson
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

3.  Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for gram-positive infections in intensive care patients.

Authors:  P Charbonneau; I Harding; J J Garaud; J Aubertin; F Brunet; Y Domart
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.